- Home
- ULS vs ROIV Comparison
ULS vs ROIV Comparison
Compare ULS & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ULS | ROIV |
|---|---|---|
| Founded | 1894 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.4B | 14.1B |
| IPO Year | 2024 | N/A |
Fundamental Metrics
Financial Performance| Metric | ULS | ROIV |
|---|---|---|
| Price | $71.00 | $22.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | ★ $80.38 | $24.31 |
| AVG Volume (30 Days) | 1.2M | ★ 5.9M |
| Earning Date | 02-19-2026 | 02-06-2026 |
| Dividend Yield | ★ 0.73% | N/A |
| EPS Growth | ★ 10.58 | N/A |
| EPS | ★ 1.67 | N/A |
| Revenue | ★ $3,003,000,000.00 | $20,329,000.00 |
| Revenue This Year | $7.18 | N/A |
| Revenue Next Year | $5.56 | $741.42 |
| P/E Ratio | $42.63 | ★ N/A |
| Revenue Growth | ★ 6.68 | N/A |
| 52 Week Low | $49.34 | $8.73 |
| 52 Week High | $91.95 | $23.91 |
Technical Indicators
Market Signals| Indicator | ULS | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 28.56 | 56.31 |
| Support Level | $71.69 | $22.50 |
| Resistance Level | $85.26 | $23.20 |
| Average True Range (ATR) | 2.67 | 0.75 |
| MACD | -1.08 | -0.01 |
| Stochastic Oscillator | 4.26 | 63.73 |
Price Performance
Historical ComparisonAbout ULS UL Solutions Inc.
UL Solutions is a global leader specializing in a broad range of product testing, inspection, and certification services. UL Solutions is the for-profit branch out of three organizations under the UL Enterprise. TIC operations make up nearly all of UL Solutions' total revenue and are composed of two segments: industrial and consumer. UL Solutions' remaining business includes software and advisory, which complements its core TIC offerings. The firm operates globally.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.